

**REMARKS**

***Preliminary matters***

Applicants wish to thank the Examiner for the courtesy extended during the personal Interview held on July 27, 2010. Applicants have prepared this supplemental Response taking into consideration the Examiner's comments during the Interview.

***Supplemental declaration evidence***

During the Interview, Applicants discussed that the DEA monomer in Lobb exhibits cytotoxicity which is worse than the cytotoxicity of the DPA of the present claims. The Examiner indicated that if this could be shown, then this aspect of the pending rejection may be overcome.

In that regard, Applicants submit the present Declaration. In the Declaration, one of the present inventors, Dr. Andrew Lewis, explains that in vitro assays have indicated that diblock copolymers comprising DPA have negligible cytotoxicities, whereas those comprising DEA are cytotoxic. Dr. Lewis explains that this was not expected from the prior art.

In view of the attached Declaration and the comments previously submitted, Applicants respectfully submit that the presently claimed invention is not anticipated or rendered obvious by the cited references.

***Conclusion***

In view of the above, the allowance of the present application is respectfully requested. The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and

the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to  
said Deposit Account.

Respectfully submitted,

A handwritten signature in dark ink, reading "Travis B. Ribar", written over a horizontal line.

Travis B. Ribar  
Registration No. 61,446

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: October 6, 2010